MoonLake Immunotherapeutics (MLTX) has emerged as a clinical-stage biotechnology company to watch, following a series of regulatory and clinical milestones that highlight the potential of its lead candidate, Sonelokimab (SLK).
Sonelokimab is a novel tri-specific Nanobody that inhibits IL-17A and IL-17F, targeting multiple inflammatory pathways. MoonLake is advancing SLK across multiple indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and palmoplantar pustulosis (PPP).
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.